Table 1 Inhibition effect of the compounds 4, 5a–5q against Xoo and Rs
From: Synthesis and biological activity of myricetin derivatives containing 1,3,4-thiadiazole scaffold
Compd. | R | Xoo | Rs | ||
|---|---|---|---|---|---|
100 μg/mL | 50 μg/mL | 100 μg/mL | 50 μg/mL | ||
2 | – | 84.5 ± 3.9 | 54.6 ± 8.5 | 46.5. ± 9.7 | 28.1 ± 7.8 |
3a | H | 84.9 ± 5.8 | 60.1 ± 2.5 | 36.0 ± 2.6 | 32.4 ± 6.1 |
3b | 4-NO2Ph | 81.4 ± 4.6 | 65.2 ± 9.0 | 81.5 ± 6.7 | 60.2 ± 6.9 |
3c | 2-MePh | 47.2 ± 1.5 | 25.9 ± 3.7 | 49.3 ± 6.7 | 30.3 ± 3.8 |
3d | 4-ClPh | 99.6 ± 0.1 | 90.7 ± 4.0 | 64.3 ± 8.8 | 30.4 ± 4.1 |
3e | Me | 58.2 ± 5.1 | 27.4 ± 5.4 | 75.7 ± 8.1 | 65.5 ± 9.9 |
3f | 2-ClPh | 87.3 ± 2.5 | 82.6 ± 2.6 | 69.3 ± 0.8 | 46.5 ± 9.1 |
3g | 2-FPh | 79.7 ± 3.6 | 21.0 ± 4.9 | 45.2 ± 5.9 | 38.3 ± 2.4 |
3h | 4-OMePh | 37.3 ± 6.2 | 15.5 ± 8.9 | 28.1 ± 7.6 | 27.1 ± 6.0 |
3i | 2,4-di-ClPh | 77.5 ± 1.4 | 68.2 ± 5.4 | 64.3 ± 6.1 | 52.1 ± 2.8 |
3j | 3-NO2Ph | 30.0 ± 1.2 | 79.8 ± 9.7 | 45.2 ± 8.3 | 31.1 ± 4.3 |
3k | 4-BrPh | 47.3 ± 4.7 | 23.3 ± 7.5 | 26.4 ± 2.6 | 10.7 ± 1.6 |
3l | 2-BrPh | 50.7 ± 1.9 | 31.6 ± 4.5 | 24.0 ± 4.7 | 16.2 ± 0.7 |
3m | 2-Cl-thiazol-5-yl | 99.4 ± 3.9 | 80.8 ± 3.7 | 26.3 ± 3.2 | 25.0 ± 6.6 |
3n | Ph | 38.3 ± 4.5 | 17.7 ± 0.1 | 45.3 ± 5.6 | 44.7 ± 5.1 |
3o | 4-MePh | 52.6 ± 3.3 | 37.6 ± 5.5 | 65.4 ± 1.7 | 52.1 ± 5.7 |
3p | Pyridin-3-yl | 84.3 ± 3.8 | 71.2 ± 5.3 | 38.0 ± 6.2 | 12.8 ± 6.0 |
Myricetin a | – | 40.1 ± 8.3 | 21.0 ± 5.6 | 28.6 ± 2.2 | 17.5 ± 3.3 |
Thiadiazole-copper a | – | 52.4 ± 2.0 | 28.7 ± 4.1 | 46.7 ± 2.0 | 32.2 ± 2.1 |